To Be Discontinued Injection Oncology

Irinotecan Hydrochloride Inj · 199 days since initial FDA posting

Brand: IRINOTECAN HYDROCHLORIDE

FDA lists Irinotecan Hydrochloride Inj as To Be Discontinued (Ingenus Pharmaceuticals LLC).

No availability text on this FDA row.

Irinotecan Hydrochloride Injection: To Be Discontinued

FDA availability text is not recorded on this row. Contact your pharmacist if you are affected.

Shortage Details

Generic Name
Irinotecan Hydrochloride Injection
Manufacturer
Ingenus Pharmaceuticals LLC
Dosage Form
Injection
Presentation
Irinotecan Hydrochloride, Injection, 40 mg/2 mL (NDC 50742-401-02)
Package NDC
50742-401-02

Status & Timeline

Status
To Be Discontinued
First Reported
Feb 24, 2026
Last Updated
Feb 24, 2026
Therapeutic Category
Oncology

Row fields from the FDA Drug Shortages database via openFDA.

Shortage Reason

A business decision was made to discontinue manufacture of the drug.

Nearby, Other Irinotecan Shortage Records

Irinotecan Hydrochloride Injection

Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)

Injection

To Be Discontinued

Irinotecan Hydrochloride Injection

Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)

Injection

To Be Discontinued

Irinotecan Hydrochloride Injection

Teva Pharmaceuticals USA, Inc.

Injection

To Be Discontinued

Irinotecan Hydrochloride Injection

Teva Pharmaceuticals USA, Inc.

Injection

To Be Discontinued

Irinotecan Hydrochloride Injection

Ingenus Pharmaceuticals LLC

Injection

To Be Discontinued

FDA reason on file: A business decision was made to discontinue manufacture of the drug. General shortage guidance lives on the tracker hub.

← All Drug Shortages